The addition of Solventum’s business provides a strategic fit with Thermo Fisher and will create value for customers, according to Marc N. Casper, chairman, president, and CEO of Thermo Fisher.

Rare Disease Day, an annual gathering hosted by the FDA and National Institutes of Health, was postponed. Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a ...

Solventum surpassed fourth-quarter revenue and earnings expectations while facing challenges in segments and regulatory ...

Solventum (NYSE:SOLV) yesterday announced fourth-quarter results that came in ahead of the consensus forecast on Wall Street.

Amy Wakeham; SVP of IR; Solventum Corp. Bryan Hanson; CEO & Director; Solventum Corp. Wayde McMillan; CFO; Solventum Corp. Jason Bednar; Analyst; Piper Sandler & Co.

Solventum Corp (SOLV) reports robust earnings per share and strategic advancements, while navigating separation complexities and market headwinds.

Minnesota-based Solventum is one of the largest providers of sterilization devices, wound dressings, medical tape and other hospital consumables used by healthcare facilities. More than half of its ...

The acquisition of Solventum’s Purification & Filtration business will allow Thermo Fisher Scientific to enhance its ...

Thermo Fisher Scientific is buying Solventum’s purification & filtration unit for $4.1 billion in cash, strengthening its ...

Thermo Fisher Scientific is expanding its life sciences portfolio by acquiring a division of Solventum that provides ...

Thermo Fisher’s release goes on to suggest that it believes it can more than double the profitability of Purification & Filtration under its corporate umbrella, relative to the business’ current ...

Activist investor Nelson Peltz's Trian Fund Management plans to push Solventum for further business separations following the company's $4.1 billion filtration unit sale, the Wall Street Journal ...